GSK Seeks To Strike Fraud Claims In Zofran MDL
GlaxoSmithKline PLC on Monday asked a Massachusetts federal court to strike fraud-based claims about its marketing of anti-nausea drug Zofran from multidistrict litigation alleging that the drug is linked to birth...To view the full article, register now.
Already a subscriber? Click here to view full article